アルツハイマー病に伴う認知症の世界市場

アルツハイマー病に伴う認知症の世界市場は2030年までに80億米ドルに達する見込み

2024年に66億米ドルと推定されるアルツハイマー病に伴う認知症の世界市場は、2024年から2030年にかけてCAGR 3.4%で成長し、2030年には80億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるコリン作動性／コリンエステラーゼ阻害剤は、CAGR 4.5%を記録し、分析期間終了時には33億米ドルに達すると予測されます。メマンチン分野の成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 6.5％で成長予測

米国のアルツハイマー病に伴う認知症市場は2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.7％と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

アルツハイマー病に伴う認知症の世界市場- 主要動向と促進要因のまとめ

アルツハイマー病に伴う認知症が世界的に公衆衛生の中心的課題として浮上しているのはなぜか？

アルツハイマー病（AD）に伴う認知症は、世界的に最も一般的な認知機能低下の形態であり、認知症診断全体の60～80％近くを占める。進行性の神経変性、記憶喪失、言語障害、実行機能障害によって特徴づけられるアルツハイマー病関連認知症は、患者、介護者、医療システムに多大な負担を強います。世界的に平均寿命が延び、高齢化社会が特に高所得国や高中所得国で拡大する中、アルツハイマー型認知症は急速に21世紀における最も差し迫った公衆衛生の危機のひとつになりつつあります。

他の慢性疾患とは異なり、認知症ケアには継続的な認知、行動、機能管理が必要であり、医学的な問題であるだけでなく、社会経済的にも重大な課題となっています。急性期治療から長期的な認知機能サポートへのシフトは、集学的ケアパス、疾患修飾療法、早期診断ツール、介護者の介入に対する要求を強めています。その結果、アルツハイマー型認知症市場は、技術革新、人口動態の変化、高齢化経済圏の政策再編成に牽引され、変貌を遂げつつあります。

どのような革新が診断、疾患調節、患者管理を変革しているのか？

アルツハイマー型認知症の診断の状況は、神経画像、体液バイオマーカー、認知機能評価技術の進歩によって再構築されつつあります。アミロイドベータとタウの沈着に対するPET検査とMRIを用いた容積分析により、より早く、より確定的な診断が可能になってきています。さらに、脳脊髄液（CSF）アッセイや、血漿Aβ42/40やリン酸化タウのような血液ベースの新しいバイオマーカーは、侵襲性の低い診断代替法を提供し、より広範なスクリーニングや早期介入戦略をサポートしています。

治療面では、疾患を修飾する治療法の出現は、数十年にわたる対症療法からの大きな脱却を意味します。ベータアミロイドの蓄積を標的とするアデュカヌマブやレカネマブなどのモノクローナル抗体のFDAによる早期承認は、アミロイドやタウを標的とした治療法に対する世界の関心に火をつけた。有効性については議論が続いているが、これらの承認は、単に症状を緩和するのではなく、認知機能低下を遅らせるというパラダイムシフトを意味します。

デジタル治療薬、バーチャルリアリティによる認知トレーニング、AIを用いたモニタリングプラットフォームは、軽度から中等度の認知症の管理において支持を集めています。モバイルアプリ、ウェアラブル、アンビエントセンサーシステムは現在、患者の行動を追跡し、異常を検知し、服薬アドヒアランスをサポートするために使用されています。薬理学的な進歩も、神経細胞の減少を止めたり逆転させたりすることを目的とした神経炎症調節剤、シナプス機能増強剤、神経保護剤において進行中です。

主な利害関係者は誰で、ケア提供モデルは世界的にどのように進化しているのか？

アルツハイマー型認知症のエコシステムには、製薬会社、バイオテクノロジー・イノベーター、診断薬開発者、神経科医、老人専門医、メモリークリニック、介護施設、医療保険者、患者擁護団体などが含まれます。政府機関、公衆衛生機関、学術研究機関もまた、臨床試験への資金提供、縦断的データセットの作成、治療ガイドラインの策定において重要な役割を果たしています。

地域別では、北米が強力な研究開発インフラ、規制の枠組み、先進的な医療提供モデルに支えられ、治療法の革新でリードしています。米国メディケア・メディケイド・サービスセンター（CMS）やNIHが支援するAMP-AD（Accelerating Medicines Partnership）などのイニシアチブが、バイオマーカー開発と患者登録の拡大に拍車をかけています。欧州では、欧州連合（EU）の「ホライゾン・欧州（Horizon Europe）」プログラムの下で認知症戦略が協調され、診断薬や長期ケアモデルにおける国境を越えた協力が促進されています。

アジア太平洋地域では、特に日本、韓国、中国において、人口動態の高齢化による患者数の急速な増加が見られます。これらの地域では、メモリーケアユニット、家族ベースの介護者トレーニング、文化に合わせたデジタル認知療法への投資が進んでいます。WHOや地域のNGOによる取り組みにより、認知度、地域社会でのスクリーニング、支援ケアへのアクセスが改善されつつあるが、新興経済圏ではアルツハイマー型認知症の診断や治療がまだ不十分です。

神経学、精神医学、作業療法、社会サービスを統合した学際的ケアモデルは、遠隔医療プラットフォーム、メモリークリニック、在宅医療ソリューションを通じて拡大しつつあります。介護者支援プログラム、レスパイトケアサービス、介護者教育プラットフォームも、家族が認知症管理の一次情報源であることに変わりはないため、世界的に重要性を増しています。

何がアルツハイマー型認知症市場の世界的成長を牽引しているのか？

アルツハイマー病関連認知症市場の成長は、人口動態の高齢化、疾患認知度の向上、早期診断と治療イノベーションの進歩の合流によってもたらされます。アルツハイマー型認知症の世界の有病率は2050年までに3倍になると予測されており、特に急速に高齢化が進み、老年医療インフラが不十分な国々ではその傾向が顕著です。この軌跡は、ヘルスケア能力構築、公衆衛生サーベイランス、薬理学的イノベーションへの緊急投資を促しています。

バイオマーカー検証や精密診断における画期的な進歩は、臨床試験デザイン、患者層別化、治療の個別化を改善し、離脱率を低下させ、疾患修飾薬候補に対する規制当局の信頼を高めています。アルツハイマー病協会のような組織からのアドボカシーに後押しされた公的および民間セクターの資金調達の増加は、治療薬候補とデジタルソリューションの強固なパイプラインを維持しています。

さらに、生産性の低下、介護者のストレス、施設入所費用、医療制度の負担に反映されるアルツハイマー型認知症の経済的負担は、各国政府に国家認知症戦略、償還モデル、介護保険の枠組みを開発させる動機となっています。新しい治療法が治験から臨床へと移行し、デジタルツールと生物学的ツールが融合するにつれて、市場は症状の緩和から疾患の阻止へと移行し、より積極的で統合的なアルツハイマー型認知症ケアのパラダイムへの道を開くと予想されます。

セグメント

薬剤クラス（コリン作動性／コリンエステラーゼ阻害薬、メマンチン、薬剤クラス別、その他の薬剤クラス）、流通チャネル（病院薬局、小売、オンライン販売）

調査対象企業の例（合計41社を掲載）

• AbbVie Inc.
• AC Immune SA
• Alector Therapeutics, Inc.
• Amgen Inc.
• Axsome Therapeutics, Inc.
• Biogen Inc.
• BioVie Inc.
• Cassava Sciences, Inc.
• Cognition Therapeutics, Inc.
• Daiichi Sankyo Company, Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Karuna Therapeutics, Inc.
• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer Inc.
• TauRx Therapeutics Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Dementia Associated with Alzheimer's Disease Market to Reach US$8.0 Billion by 2030

The global market for Dementia Associated with Alzheimer's Disease estimated at US$6.6 Billion in the year 2024, is expected to reach US$8.0 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Cholinergic / Cholinesterase Inhibitors, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Memantine segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 6.5% CAGR

The Dementia Associated with Alzheimer's Disease market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Dementia Associated With Alzheimer’s Disease Market - Key Trends & Drivers Summarized

Why Is Alzheimer’s-Associated Dementia Emerging as a Central Public Health Challenge Worldwide?

Dementia associated with Alzheimer’s disease (AD) represents the most prevalent form of cognitive decline globally, accounting for nearly 60% to 80% of all dementia diagnoses. Characterized by progressive neurodegeneration, memory loss, language impairment, and executive dysfunction, Alzheimer’s-related dementia imposes an immense burden on patients, caregivers, and health systems. As global life expectancy increases and aging populations expand-particularly in high-income and upper-middle-income countries-Alzheimer’s dementia is fast becoming one of the most pressing public health crises of the 21st century.

Unlike other chronic conditions, dementia care requires continuous cognitive, behavioral, and functional management, making it not only a medical issue but a profound socioeconomic challenge. The shift from acute treatment to long-term cognitive support has intensified demand for multidisciplinary care pathways, disease-modifying therapies, early diagnostic tools, and caregiver interventions. Consequently, the Alzheimer’s-associated dementia market is undergoing transformation-driven by innovation, demographic shifts, and policy realignment across aging economies.

What Innovations Are Transforming Diagnosis, Disease Modulation, and Patient Management?

The diagnostic landscape for Alzheimer’s dementia is being reshaped by advances in neuroimaging, fluid biomarkers, and cognitive assessment technologies. PET scans for amyloid-beta and tau deposition, along with MRI-based volumetric analysis, are enabling earlier and more definitive diagnoses. Additionally, cerebrospinal fluid (CSF) assays and emerging blood-based biomarkers such as plasma Aβ42/40 and phosphorylated tau are offering less invasive diagnostic alternatives-supporting broader screening and early intervention strategies.

On the therapeutic front, the emergence of disease-modifying treatments marks a significant departure from decades of symptomatic care. The FDA’s accelerated approval of monoclonal antibodies such as aducanumab and lecanemab, which target beta-amyloid accumulation, has ignited global interest in amyloid- and tau-directed therapies. Although efficacy debates persist, these approvals represent a paradigm shift toward slowing cognitive decline, rather than merely alleviating symptoms.

Digital therapeutics, virtual reality cognitive training, and AI-based monitoring platforms are gaining traction in managing mild-to-moderate dementia stages. Mobile apps, wearables, and ambient sensor systems are now being used to track patient behavior, detect anomalies, and support medication adherence. Pharmacological advancements are also underway in neuroinflammation modulators, synaptic function enhancers, and neuroprotective agents aimed at halting or reversing neuronal loss.

Who Are the Key Stakeholders and How Are Care Delivery Models Evolving Globally?

The Alzheimer’s dementia ecosystem includes pharmaceutical companies, biotechnology innovators, diagnostic developers, neurologists, geriatric specialists, memory clinics, assisted living facilities, health insurers, and patient advocacy groups. Government agencies, public health organizations, and academic research institutions also play instrumental roles in funding trials, generating longitudinal datasets, and shaping treatment guidelines.

Regionally, North America leads in therapeutic innovation, supported by strong R&D infrastructure, regulatory frameworks, and advanced care delivery models. The U.S. Centers for Medicare & Medicaid Services (CMS) and NIH-backed initiatives like the Accelerating Medicines Partnership (AMP-AD) have catalyzed biomarker development and patient registry expansions. In Europe, coordinated dementia strategies under the European Union’s Horizon Europe program are fostering cross-border collaboration in diagnostics and long-term care models.

Asia-Pacific is experiencing rapid growth in patient numbers due to demographic aging, especially in Japan, South Korea, and China. These regions are investing in memory care units, family-based caregiver training, and culturally tailored digital cognitive therapies. In emerging economies, Alzheimer’s dementia remains underdiagnosed and undertreated, though initiatives by the WHO and regional NGOs are improving awareness, community screening, and access to supportive care.

Multidisciplinary models of care-integrating neurology, psychiatry, occupational therapy, and social services-are being scaled through telemedicine platforms, memory clinics, and home-based health solutions. Caregiver support programs, respite care services, and caregiver education platforms are also gaining importance as families remain the primary source of dementia management globally.

What Is Driving the Growth in the Alzheimer’s-Associated Dementia Market Globally?

The growth in the Alzheimer’s-associated dementia market is driven by a confluence of aging demographics, increasing disease awareness, and advances in early diagnosis and therapeutic innovation. The global prevalence of Alzheimer’s dementia is projected to triple by 2050, especially in countries with rapidly aging populations and inadequate geriatric infrastructure. This trajectory is prompting urgent investments in healthcare capacity building, public health surveillance, and pharmacological innovation.

Breakthroughs in biomarker validation and precision diagnostics are improving clinical trial design, patient stratification, and treatment personalization-reducing attrition rates and enhancing regulatory confidence in disease-modifying drug candidates. The rise in public and private sector funding, spurred by advocacy from organizations like the Alzheimer’s Association, is sustaining a robust pipeline of therapeutic candidates and digital solutions.

Furthermore, the economic burden of Alzheimer’s dementia-reflected in productivity loss, caregiver stress, institutionalization costs, and health system strain-is motivating governments to develop national dementia strategies, reimbursement models, and long-term care insurance frameworks. As new therapies transition from trial to clinic, and as digital and biological tools converge, the market is expected to transition from symptom relief to disease interception, paving the way for a more proactive and integrated Alzheimer’s dementia care paradigm.

SCOPE OF STUDY:

The report analyzes the Dementia Associated with Alzheimer's Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail, Online Sales)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• AC Immune SA
• Alector Therapeutics, Inc.
• Amgen Inc.
• Axsome Therapeutics, Inc.
• Biogen Inc.
• BioVie Inc.
• Cassava Sciences, Inc.
• Cognition Therapeutics, Inc.
• Daiichi Sankyo Company, Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Karuna Therapeutics, Inc.
• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer Inc.
• TauRx Therapeutics Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Dementia Associated with Alzheimer's Disease - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Aging Population and Cognitive Health Awareness Propel Focus on Alzheimer's-Linked Dementia Treatment
  • Expansion of Early Diagnostic Tools and Biomarkers Throws the Spotlight on Disease-Modifying Therapies
  • OEM Development of Amyloid-Targeting and Tau-Based Biologics Strengthens Clinical Pipeline Momentum
  • Growth in Companion Diagnostics and Imaging Techniques Enhances Precision Treatment Pathways
  • Rising Approvals for Disease-Modifying Therapies Fuels Shift From Symptomatic to Curative Approaches
  • OEM Investment in Oral and Intravenous Formulations Improves Dosing Options and Accessibility
  • Expansion of Home-Based and Digital Cognitive Monitoring Supports Early Stage Intervention Models
  • Growth in Government Funding and Fast-Track Drug Review Designations Accelerates Product Development
  • OEM Partnerships With Neuroscience Research Institutions Drive Biomarker Discovery
  • Surge in AI-Based Drug Repurposing Platforms Supports Alzheimer's Drug Pipeline Diversification
  • Increasing Focus on Neuroinflammation and Mitochondrial Pathways Opens New Mechanistic Targets
  • OEM Integration of Real-World Evidence Collection Enhances Longitudinal Treatment Outcome Assessment
  • Expansion of Behavioral and Functional Therapy Integration Enhances Multimodal Care Delivery
  • Regulatory Push for High-Risk, High-Reward Trial Frameworks Encourages Investment in Complex Neurotherapies
  • OEM Emphasis on Combination Therapy Strategies Improves Long-Term Efficacy and Safety Profiles
  • Rising Use of Digital Therapeutics and Brain Health Apps Complements Pharmacological Interventions
  • Growth in Genetic Testing for Alzheimer's Risk Prediction Expands Preventive and Lifestyle-Based Markets
  • OEM Collaboration With Caregiver Networks and Support Groups Enhances Holistic Patient Engagement
  • Focus on Health Equity and Early Detection in Underserved Communities Expands Diagnostic Outreach
  • Global Growth in Memory Clinics and Geriatric Neurology Centers Strengthens Treatment Access and Awareness
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dementia Associated with Alzheimer's Disease Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dementia Associated with Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cholinergic / Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cholinergic / Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Cholinergic / Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Memantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Combined Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Combined Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Combined Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Sales by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• JAPAN
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Japan 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• CHINA
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: China 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• EUROPE
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Dementia Associated with Alzheimer's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• FRANCE
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: France 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• GERMANY
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Germany 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Italy 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: UK 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Spain 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Spain 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Russia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Russia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Dementia Associated with Alzheimer's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Australia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Australia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• INDIA
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: India 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: India 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: South Korea 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: South Korea 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Dementia Associated with Alzheimer's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Latin America 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Latin America 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Argentina 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Argentina 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Brazil 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Brazil 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Mexico 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Mexico 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Dementia Associated with Alzheimer's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Middle East 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Middle East 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Iran 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Iran 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Israel 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Israel 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: UAE 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: UAE 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030
• AFRICA
  • Dementia Associated with Alzheimer's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Dementia Associated with Alzheimer's Disease by Drug Class - Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Africa 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Drug Class - Percentage Breakdown of Value Sales for Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Dementia Associated with Alzheimer's Disease by Distribution Channel - Hospital Pharmacies, Retail and Online Sales Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Africa 15-Year Perspective for Dementia Associated with Alzheimer's Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail and Online Sales for the Years 2015, 2025 & 2030

IV. COMPETITION